Degassed liquids to prevent/treat decompression sickness

Medical Hypotheses

Volumn 60, Issue 5, 2003, Pages 720-723

  Watenpaugh, Donald E ^a  

^a Naval Submarine Base New London   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; DEXTRAN 40; DEXTRAN 70; FLUOROCARBON; GLUCOSE; ISOTONIC SOLUTION; MANNITOL; NITROGEN; PERFLUOROOCTYL BROMIDE; RINGER LACTATE SOLUTION; SODIUM CHLORIDE;

ARTERIAL GAS; ARTICLE; BLOOD VISCOSITY; BRAIN EMBOLISM; DECOMPRESSION; DECOMPRESSION SICKNESS; DIVING; DOG; GAS ANALYSIS; GAS DIFFUSION; GAS EMBOLISM; HEMOCONCENTRATION; HUMAN; HYPOTHESIS; INFUSION; INGESTION; LIQUID; NONHUMAN; OXYGEN BREATHING; PRIORITY JOURNAL; SUBSTITUTION THERAPY; THEORETICAL STUDY; TISSUE PERFUSION;

EID: 0037403203     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00045-8     Document Type: Article

References (31)

1. P. B. Bennett, D. H. Elliott (eds). The Physiology and Medicine of Diving, 4th Edn. London: W.B. Saunders Company, 1993.
2. Lamy M. L., Hanquet M. M. Modern aspects of treatment of decompression sickness. Acta Anaesthesiol Belg 1973; 24: 215-229.
3. Hills B. A. Decompression Sickness , Volume 1: The Biophysical Basis of Prevention and Treatment. Chichester: Wiley, 1977.
4. Bove A. A. The basis for drug therapy in decompression sickness. Undersea Biomed Res 1982; 9: 91-111.
5. Watenpaugh D. E., Pump B., Bie P., Norsk P. Does gender influence human cardiovascular and renal responses to water immersion? J Appl Physiol 2000; 89: 621-628.
6. Knight D. R., Horvath S. M. Urinary responses to cold temperature during water immersion. Am J Physiol 1985; 248: R560-566.
7. Cockett A. T., Pauley S. M., Zehl D. N., Pilmanis A. A., Cockett W. S. Pathophysiology of bends and decompression sickness. An overview with emphasis on treatment. Arch Surg 1979; 114: 296-301.
8. Catron P. W., Flynn E. T., Jr Adjuvant drug therapy for decompression sickness: a review. Undersea Biomed Res 1982; 9: 161-174.
9. Merton D. A., Fife W. P., Gross D. R. An evaluation of plasma volume expanders in the treatment of decompression sickness. Aviat Space Environ Med 1983; 54: 218-222.
10. Cooke J. P., Olson R. M., Holden R. D. Intravascular bubbles associated with intravenous injections and altitude. Aviat Space Environ Med 1976; 47: 974-978.
11. Gorman D. F. Management of diving accidents. In: P. B. Bennett, D. H. Elliott (eds). The Physiology and Medicine of Diving, 4th Edn. London: W.B. Saunders Company, 1993: 253-266.
12. Kindwall E. P., Margolis I. Management of severe decompression sickness with treatment ancillary to recompression: case report. Aviat Space Environ Med 1975; 46: 1065-1068.
13. Saumarez R. C., Bolt J. F., Gregory R. J. Neurological decompression sickness treated without recompression. Br Med J 1973; 1: 151-152.
14. Cockett A. T. Pathophysiology of shock secondary to underwater decompression sickness. Bull Soc Int Chir 1973; 32: 229-237.
15. Lynch P. R., Krasner L. J., Vinciquerra T., Shaffer T. H. Effects of intravenous perfluorocarbon and oxygen breathing on acute decompression sickness in the hamster. Undersea Biomed Res 1989; 16: 275-281.
16. Cassuto Y., Nunneley S. A., Farhi L. E. Inert gas washout in rats: enhancement by fluorocarbon infusion. Aerosp Med 1974; 45: 12-14.
17. Spiess B. D., Braverman B., Woronowicz A. W., Ivankovich A. D. Protection from cerebral air emboli with perfluorocarbons in rabbits. Stroke 1986; 17: 1146-1149.
18. Spiess B. D., Mccarthy R., Piotrowski D., Ivankovich A. D. Protection from venous air embolism with fluorocarbon emulsion FC-43. J Surg Res 1986; 41: 439-444.
19. Weathersby P. K., Homer L. D. Solubility of inert gases in biological fluids and tissues: a review. Undersea Biomed Res 1980; 7: 277-296.
20. Shilling C. W., Werts M. F., Schandelmeier N. R. The Underwater Handbook. A Guide to Physiology and Performance for the Engineer. New York: Plenum Press, 1976.
21. Hills B. A., Butler B. D. Size distribution of intravascular air emboli produced by decompression. Undersea Biomed Res 1981; 8: 163-170.
22. Sargent J. W., Seffl R. J. Properties of perfluorinated liquids. Fed Proc 1970; 29: 1699-1703.
23. Lutz J., Herrmann G. Perfluorochemicals as a treatment of decompression sickness in rats. Pflugers Arch Gesamte Physiol Menschen Tiere 1984; 401: 174-177.
24. 2 elimination. Undersea Biomed Res 1991; 18: 279-292.
25. Mattrey R. F., Trambert M. A., Brown J. J. et al. Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial. Radiology 1994; 191: 841-848.
26. Bisset III G. S., Emery K. H., Meza M. P., Rollins N. K., Don S., Shorr J. S. Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population. Pediatr Radiol 1996; 26: 409-415.
27. Shaffer T. H., Wolfson M. R. Control, Treatment and/or Diagnosis of Physiological Conditions with Degassed Perfluorocarbon Liquid. US patent number 5,350,359. Philadelphia, PA: Temple University, 1994.
28. Harada H. Sonochemical reduction of carbon dioxide. Ultrason Sonochem 1998; 5: 73-77.
29. Watenpaugh D. E., Yancy C. W., Buckey J. C., Lane L. D., Hargens A. R., Blomqvist C. G. Role of atrial natriuretic peptide in systemic responses to acute isotonic volume expansion. J Appl Physiol 1992; 73: 1218-1226.
30. Watenpaugh D. E., Gaffney F. A. Measurement of net whole-body transcapillary fluid transport and effective vascular compliance in humans. J Trauma 1998; 45: 1062-1068.
31. Dervay J. P., Powell M. R., Butler B., Fife C. E. The effect of exercise and rest duration on the generation of venous gas bubbles at altitude. Aviat Space Environ Med 2002; 73: 22-27.